ReAlta Life Sciences’ RLS-0071 Demonstrates Excellent Safety Profile and Confirmed Target Engagement in First-in-Human Phase 1 Clinical Trial
April 4, 2022RLS-0071 is a dual action complement inhibitor and innate anti-inflammatory peptide in development as a treatment for hypoxic-ischemic encephalopathy and other rare diseases
Poster Presentation at the American Academy of Neurology 2022 Annual Meeting
NORFOLK, Va.–(BUSINESS WIRE)–ReAlta Life Sciences (“ReAlta”), Inc., a clinical stage, rare disease company addressing life-threatening diseases through harnessing the power of the immune system, today announced first-in-human Phase 1 clinical data on RLS-0071, the Company’s complement inhibitor and innate anti-inflammatory product candidate. RLS-0071 demonstrated an excellent safety profile and confirmed target engagement in healthy volunteers. RLS-0071 is being developed as a treatment for hypoxic-ischemic encephalopathy (HIE) and other rare diseases. The data are being presented at the American Academy of Neurology 2022 Annual Meeting to be held in person in Seattle on April 2 to 6, 2022, and virtually on April 24 to 26, 2022. The abstract is available here.
“Results of this first-in-human study are an important step in its RLS-0071’s development because of its excellent safety profile and evidence of target engagement,” said Ulrich Thienel, M.D., Ph.D., ReAlta’s Chief Executive Officer. “With the clearance of the HIE IND last month, we are now looking forward to advancing RLS-0071 into Phase 2 development.”
RLS-0071 is a 15 amino acid peptide that inhibits both humoral inflammation by blocking classical pathway complement activation and cellular inflammation by blocking the neutrophil effectors myeloperoxidase (MPO) and neutrophil extracellular traps (NETs).
The Phase 1 trial was a single ascending dose (SAD) and multiple ascending dose (MAD) study that enrolled 56 healthy subjects of which 42 received intravenous RLS-0071 across seven cohorts in a ratio of 6 active:2 placebo. The maximum SAD dose was 120 mg/kg and the maximum MAD dose was 40 mg/kg every eight hours for nine doses.
RLS-0071 demonstrated an excellent safety profile with no treatment-related or serious adverse events or infusion-related reactions. Biomarker data and target engagement assays demonstrated time-limited dose responses for humoral and cellular-based inflammatory effectors consistent with the known mechanisms of action of RLS-00171 and with return to baseline.
Details of the presentation:
|
Title |
RLS-0071-101 a study in healthy human volunteers demonstrates safety, complement and inflammatory effector target engagement activity of this novel peptide |
|
Authors |
Kenji Cunnion1,2, Parvathi Kumar1, Neel Krishna1, Ulrich Thienel1, L. Matthew Frank2 1ReAlta Life Sciences, 2Children’s Specialty Group |
|
Presentation |
Poster #002; Neighborhood 7 |
|
Session |
P12: Neurocritical Care: COVID-19, TBI and Other Topics 2 |
|
Date/time |
Tuesday, April 5, 5:30 – 6:30 p.m. PDT |
About ReAlta Life Sciences
ReAlta Life Sciences, Inc. is a clinical-stage, rare disease biotech company dedicated to harnessing the power of the immune system to address life threatening diseases. The Company’s EPICC peptides are based on research into the human astrovirus HAstV-1, which causes a non-inflammatory, self-limiting gastroenteritis unique among viruses by inhibiting components of the innate immune system. ReAlta’s therapeutic peptides leverage these virus-derived mechanisms to rebalance complement and inflammatory processes in the body. The company’s pipeline is led by RLS-0071, which has received IND clearance, and Orphan Drug Designation by the U.S. Food and Drug Administration and European Medicines Agency for the treatment of hypoxic-ischemic encephalopathy (HIE) in neonates. The company launched in 2018 and is located in Norfolk, Virginia. For more information, please visit www.realtalifesciences.com.
Contacts
Media:
Robert Flamm, Ph.D.
Burns McClellan
Investors:
Eric Ando
Burns McClellan